Skip to content
DataLookout
Menu

NCT07200193

A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion moved earlier from Dec 31, 2032 to Feb 2031 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 8 words
    • Enrollment closed, study ongoing
    • Final enrollment: 9 participants (planned 66)
    • Trial arms changed: 3 → 1
    • Study sites: 4 to 3
    • Secondary endpoints: 18 to 12
  2. Minor Study sites: 2 to 4v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2026 to Dec 22, 2025
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and tolerability of CRMA-1001
Timeframe: 6 months

Secondary (9)

Long-term safety of CRMA-1001
Pharmacokinetics of CRMA-1001 components (Cmax)
Pharmacokinetics of CRMA-1001 components (Tmax)
Pharmacokinetics of CRMA-1001 components (terminal clearance rate)
Pharmacokinetics of CRMA-1001 components (Vd)
Show 4 moreShow less
To evaluate the immunogenicity of CRMA-1001
To evaluate the effect of CRMA-1001 on circulating HBV biomarkers (HBsAg)
To evaluate the effect of CRMA-1001 on circulating HBV biomarkers (anti-HBs)
To evaluate the effect of CRMA-1001 on circulating HBV biomarkers (HBV DNA)

Arms and interventions

Experimental: CRMA-1001Other

Single ascending dose arm

Genetic: CRMA-1001

Sites

3 sites in 3 countries

Hong Kong 1, New Zealand 1, United Kingdom 1